LLY

879.51

-2.09%↓

JNJ

239.74

+0.04%↑

ABBV

209.86

-0.59%↓

NVS

148.06

-1.14%↓

MRK

119.75

+0.73%↑

LLY

879.51

-2.09%↓

JNJ

239.74

+0.04%↑

ABBV

209.86

-0.59%↓

NVS

148.06

-1.14%↓

MRK

119.75

+0.73%↑

LLY

879.51

-2.09%↓

JNJ

239.74

+0.04%↑

ABBV

209.86

-0.59%↓

NVS

148.06

-1.14%↓

MRK

119.75

+0.73%↑

LLY

879.51

-2.09%↓

JNJ

239.74

+0.04%↑

ABBV

209.86

-0.59%↓

NVS

148.06

-1.14%↓

MRK

119.75

+0.73%↑

LLY

879.51

-2.09%↓

JNJ

239.74

+0.04%↑

ABBV

209.86

-0.59%↓

NVS

148.06

-1.14%↓

MRK

119.75

+0.73%↑

Search

CareDx Inc

Open

SectorGezondheidszorg

16.88 -3.32

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16.74

Max

17.62

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.8M

-4.1M

Verkoop

8.3M

108M

K/W

Sectorgemiddelde

14.645

57.05

EPS

0.12

Winstmarge

-3.79

Werknemers

761

EBITDA

-5.7M

1.5M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+38.27% upside

Dividenden

By Dow Jones

Volgende Winsten

29 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-97M

903M

Vorige openingsprijs

20.2

Vorige sluitingsprijs

16.88

Nieuwssentiment

By Acuity

34%

66%

110 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 mrt 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 mrt 2026, 23:36 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 mrt 2026, 23:35 UTC

Acquisities, Fusies, Overnames

Pernod Ricard: Confirms Discussions With Brown-Forman

26 mrt 2026, 23:29 UTC

Winsten

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 mrt 2026, 23:28 UTC

Winsten

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 mrt 2026, 23:28 UTC

Winsten

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 mrt 2026, 23:28 UTC

Winsten

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 mrt 2026, 23:27 UTC

Winsten

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 mrt 2026, 23:27 UTC

Winsten

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 mrt 2026, 23:08 UTC

Marktinformatie

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 mrt 2026, 23:04 UTC

Acquisities, Fusies, Overnames

Pernod in Deal Talks With Brown-Forman -- WSJ

26 mrt 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 mrt 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 mrt 2026, 22:26 UTC

Winsten

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 mrt 2026, 22:26 UTC

Winsten

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 mrt 2026, 22:26 UTC

Winsten

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 mrt 2026, 22:08 UTC

Winsten

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 mrt 2026, 22:08 UTC

Winsten

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 mrt 2026, 22:08 UTC

Winsten

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 mrt 2026, 22:07 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Energy Roundup: Market Talk

26 mrt 2026, 22:07 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 mrt 2026, 22:00 UTC

Winsten

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 mrt 2026, 22:00 UTC

Winsten

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 mrt 2026, 22:00 UTC

Winsten

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 mrt 2026, 21:38 UTC

Acquisities, Fusies, Overnames

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

38.27% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25 USD  38.27%

Hoogste 28 USD

Laagste 21 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

2

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

110 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat